Emera Incorporated
EMRAF
$41.20
$0.330.81%
| Weiss Ratings | EMRAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Weak | |||
| Risk Grade | D+ | |||
| Reward Grade | B- | |||
| Rating Factors | EMRAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Good | |||
| Growth Index | Fair | |||
| Efficiency Index | Good | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | EMRAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.51 | |||
| Price History | EMRAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.24% | |||
| 30-Day Total Return | 9.23% | |||
| 60-Day Total Return | 8.72% | |||
| 90-Day Total Return | 12.00% | |||
| Year to Date Total Return | 12.35% | |||
| 1-Year Total Return | 24.51% | |||
| 2-Year Total Return | 15.86% | |||
| 3-Year Total Return | 2.19% | |||
| 5-Year Total Return | 51.77% | |||
| 52-Week High % Change | -0.43% | |||
| 52-Week Low % Change | 28.75% | |||
| Price | EMRAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $41.38 | |||
| 52-Week Low Price | $32.00 | |||
| 52-Week Low Price (Date) | Apr 18, 2024 | |||
| 52-Week High Price (Date) | Mar 10, 2025 | |||
| Valuation | EMRAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 12.32B | |||
| Enterprise Value | 26.99B | |||
| Price/Earnings (TTM) | 33.03 | |||
| Earnings Per Share (TTM) | 1.25 | |||
| Earnings Per Share Growth | -52.78% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 2.30 | |||
| Price/Book (Q) | 1.48 | |||
| Enterprise Value/Revenue (TTM) | 5.13 | |||
| Price | $41.20 | |||
| Enterprise Value/EBITDA (TTM) | 14.59 | |||
| Enterprise Value/EBIT | 27.00 | |||
| Market Cap Category | Large Cap | |||
| Dividends and Shares | EMRAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 294.00M | |||
| Dividend Yield | 5.04% | |||
| Div. Per Share (Most Recent) | $0.51 | |||
| Dividend Per Share (TTM) | $2.08 | |||
| Payout Ratio (TTM) | 107.70% | |||
| Dividend Per Share (Most Recent) | $0.51 | |||
| Company Info | EMRAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 902-428-6096 | |||
| Address | Emera Place Halifax, NS B3J 1A1 | |||
| Website | www.emera.com | |||
| Country | Canada | |||
| Year Founded | 1998 | |||
| Profitability | EMRAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 19.01% | |||
| Profit Margin | 7.87% | |||
| Management Effectiveness | EMRAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 2.09% | |||
| Return on Equity | 4.51% | |||
| Income Statement | EMRAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 5.26B | |||
| Total Revenue (TTM) | 5.26B | |||
| Revenue Per Share | $17.89 | |||
| Gross Profit (TTM) | 2.12B | |||
| EBITDA (TTM) | 1.85B | |||
| EBIT (TTM) | 999.80M | |||
| Net Income (TTM) | 414.03M | |||
| Net Income Avl. to Common (TTM) | 360.76M | |||
| Total Revenue Growth (Q YOY) | -13.11% | |||
| Earnings Growth (Q YOY) | -45.23% | |||
| EPS Diluted (TTM) | 1.25 | |||
| EPS Diluted Growth (Q YOY) | -51.02% | |||
| Balance Sheet | EMRAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 136.22M | |||
| Cash Per Share (Q) | $0.46 | |||
| Total Current Assets (Q) | 2.56B | |||
| Total Preferred Equity (Q) | 988.30 | |||
| Total Equity (Q) | 9.24B | |||
| Current Ratio (Q) | 0.721 | |||
| Book Value Per Share (Q) | $27.84 | |||
| Total Assets (Q) | 29.85B | |||
| Total Current Liabilities (Q) | 3.55B | |||
| Total Debt (Q) | 13.81B | |||
| Total Liabilities (Q) | 20.61B | |||
| Total Common Equity (Q) | 8.24B | |||
| Cash Flow | EMRAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -1.61B | |||
| Cash from Financing (TTM) | -603.88M | |||
| Net Change in Cash (TTM) | -271.18M | |||
| Levered Free Cash Flow (TTM) | -730.36M | |||
| Cash from Operations (TTM) | 1.93B | |||
